Home > Boards > US Listed > Biotechs > Stemline Therapeutics (STML)

$STML $22.66 Bought a small position @ $21.39,

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
$$$eeker Member Profile
 
Followed By 28
Posts 2,698
Boards Moderated 0
Alias Born 04/09/10
160x600 placeholder
Stemline Therapeutics Announces ELZONRIS® Clinical Data Selected for Oral Presentation at the 81st Annual Meeting of the Jap... GlobeNewswire Inc. - 10/8/2019 7:30:00 AM
Stemline Therapeutics Recaps Felezonexor (SL-801) Clinical Data Presentation From ESMO 2019 Congress GlobeNewswire Inc. - 10/1/2019 7:30:00 AM
Stemline Therapeutics Announces Felezonexor (SL-801) Clinical Data to be Featured at Upcoming ESMO 2019 Congress GlobeNewswire Inc. - 9/27/2019 7:30:00 AM
Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 4:01:00 PM
Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 9:32:15 AM
Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference GlobeNewswire Inc. - 9/5/2019 7:30:00 AM
Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference GlobeNewswire Inc. - 8/9/2019 4:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/9/2019 1:18:00 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/9/2019 1:16:29 PM
Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock GlobeNewswire Inc. - 8/8/2019 10:23:47 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 8/8/2019 6:10:20 AM
Stemline Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire Inc. - 8/7/2019 4:25:03 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/6/2019 4:37:16 PM
Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS® GlobeNewswire Inc. - 8/6/2019 7:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/2/2019 7:31:04 AM
Stemline Therapeutics Reports Second Quarter 2019 Financial Results GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019 GlobeNewswire Inc. - 7/29/2019 7:00:00 AM
Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its An... GlobeNewswire Inc. - 7/8/2019 5:50:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:18:38 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:55 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:17:07 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:47 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:21 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/28/2019 5:16:09 PM
$$$eeker   Friday, 02/07/14 11:28:07 AM
Re: None
Post # of 67 
$STML $22.66 Bought a small position @ $21.39, appears to have bottomed.

Balance Sheet
Total Cash (mrq): 87.67M
Total Cash Per Share (mrq): 6.93
Total Debt (mrq): 0.00
Total Debt/Equity (mrq): N/A
Current Ratio (mrq): 31.09
Book Value Per Share (mrq): 6.81

Share Statistics
Avg Vol (3 month)3: 219,929
Avg Vol (10 day)3: 201,762
Shares Outstanding5: 12.66M
Float: 9.62M
% Held by Insiders1: 9.68%
% Held by Institutions1: 11.20%
Shares Short (as of Jan 15, 2014)3: 424.19K
Short Ratio (as of Jan 15, 2014)3: 3.00
Short % of Float (as of Jan 15, 2014)3: 7.50%

Recommendation Summary*
Mean Recommendation (this week): 2.3
Mean Recommendation (last week): 2.3
Change: 0.0
* (Strong Buy) 1.0 - 5.0 (Sell)

Price Target Summary
Mean Target: 33.75
Median Target: 38.00
High Target: 50.00
Low Target: 9.00
No. of Brokers: 4
Data provided by Thomson/First Call

Upgrades & Downgrades History
Date Research Firm Action From To
Aug 29, 2013 Jefferies Initiated Buy
Jul 29, 2013 Roth Capital Initiated Buy
Jun 18, 2013 Ladenburg Thalmann Initiated Buy
Mar 18, 2013 Aegis Capital Initiated Buy
Feb 12, 2013 WBB Securities Initiated Sell

http://yhoo.it/MxG6K9

NEW YORK, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 16th Annual Biotechnology Industry Organization (BIO) CEO & Investor Conference on Tuesday, February 11, 2014 at 11:30 AM ET. The conference will be held at the Waldorf Astoria in New York on February 10-11, 2014. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.

NEW YORK, Feb. 6, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 3:30 PM ET. The conference will be held at the Waldorf Astoria in New York City. A live webcast of the presentation can be viewed on the Company's website at www.stemline.com.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist